Medpace Holdings, Inc. filed its quarterly report on Form 10-Q with the SEC on October 22, 2026, covering the three and nine months ended September 30, 2026, and reporting third-quarter net revenue of $716.0 million and net income of $137.5 million.

Key Highlights

  • Q3 2026 net revenue: $716.0 million, compared to $659.9 million in Q3 2025, according to the filing.
  • Q3 2026 net income: $137.5 million, versus $111.1 million in the prior-year quarter, as reported.
  • Diluted EPS for Q3 2026: $4.84, compared to $3.86 for Q3 2025, per the filing.
  • Nine-month net revenue: $2,129.9 million for the nine months ended September 30, 2026, up from $1,821.8 million in the same period of 2025.
  • Cash and cash equivalents: $705.3 million as of September 30, 2026, versus $497.0 million at December 31, 2025.
  • Total assets: $2,302.6 million at September 30, 2026, compared to $1,975.5 million at December 31, 2025.
  • Shares outstanding: 27,971,686 shares of common stock as of October 16, 2026, per the cover page.

Medpace Holdings Third-Quarter 2026 Financial Results and Balance Sheet

According to the Form 10-Q filed for the quarterly period ended September 30, 2026, Medpace Holdings, Inc. (NASDAQ:MEDP) reported net revenue of $716.0 million for the three months ended September 30, 2026, compared to $659.9 million for the same quarter in 2025. The filing noted that revenue included $3.8 million with related parties in Q3 2026, versus $12.2 million with related parties in Q3 2025. For the nine months ended September 30, 2026, the company reported net revenue of $2,129.9 million, up from $1,821.8 million in the same period of 2025.

Income from operations for Q3 2026 was $165.5 million, compared to $141.8 million in Q3 2025, the filing disclosed. Total operating expenses for the quarter were $550.5 million, including direct service costs of $204.9 million, reimbursed out-of-pocket expenses of $287.3 million, selling, general and administrative costs of $51.8 million, depreciation of $6.4 million, and amortization of $155 thousand. Net income for Q3 2026 was $137.5 million, with basic earnings per share of $4.92 and diluted earnings per share of $4.84, according to the filing.

On the balance sheet as of September 30, 2026, the company reported total assets of $2,302.6 million and total liabilities of $1,717.7 million, resulting in total shareholders' equity of $584.9 million, as disclosed in the filing. Advanced billings stood at $961.9 million, compared to $854.4 million at December 31, 2025. The accumulated deficit was reported at $373.6 million as of September 30, 2026, compared to $460.0 million at December 31, 2025. Common shares issued and outstanding were 27,966,686 at September 30, 2026, down from 28,370,780 at December 31, 2025, reflecting share repurchase activity during the period.

What Was Disclosed

Medpace Holdings filed its Form 10-Q for the quarter ended September 30, 2026, disclosing third-quarter net revenue of $716.0 million, net income of $137.5 million, diluted EPS of $4.84, and total assets of $2,302.6 million, with cash of $705.3 million.